X
NHS England takes charge on market access
https://pharmaphorum.com/views-analysis-market-access/perjeta-benefits-nhs-england-takes-charge/
Pharma Market Access
Market Access
NICE numbers: trends in recommendations should prompt a review of NICE
Should there be a different review of NICE as part of a successor PPRS?
NHS to trial digital depression tool Deprexis
NICE recommends two-year trial of Gaia Healthcare product
NICE must be reformed – Janssen UK market access chief
Janssen’s UK pricing chief Jennifer Lee has called for reform of NICE following the company’s successful but drawn-out attempt to get its cancer drug Darzalex to NHS patients.
Balancing cost:benefit in ‘well-treated’ malignancies
The cost: benefit ratio of the rising prices of new oncology treatments and how the pharmaceutical industry and regulators can adequately address them.
We should quit Brexit, it’s bad for our health
Public health experts and UK life science leaders are reiterating concerns about Brexit’s threat to the nation’s health.